Nanyang Biologics, a Singapore-based artificial intelligence drug discovery start-up, plans to list on the Nasdaq stock exchange in the first quarter of 2026 via a merger with a US-listed special-purpose acquisition company (SPAC), as US President Donald Trump vowed to impose hefty tariffs on pharmaceutical imports. "The US administration wants intellectual property owners to manufacture in the US, including drugs," founder Roland Ong said on Monday. Nanyang Biologic's latest initiative reflects its effo ...